Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed early-stage interim ...

GEN Live panelists will explore how stem cells are transforming disease modeling, drug discovery, and personalized medicine with perspectives on clinical trial progress and hurdles such as ...

The data showed that roughly 65% of the cells in the oxygenated devices remained viable compared to roughly 20% in control devices.

Study findings indicate that environmentally relevant doses of OLA bioplastics may be “more toxic” to the placenta than ...

Whether Judge Murphy’s ruling holds through appeal will determine how much institutional credibility can be recovered.

Researchers suggest modulating intestinal microbiota or antigen-presenting activity of IECs represents new approaches to treating autoimmune neurological disease.

Beyond resistance‑associated genes, the researchers uncovered deep geographic population structure and high overall genetic diversity.

UCB has achieved 15 FDA approvals or indication expansions, nine of which were secured in the past three years.

The data shows that inhibiting TIE2 with rebastinib could prevent new abnormalities from forming in the brain with fewer side effects.

A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward the tumor.

Many organizations still lack structured media optimization and alignment between development and manufacturing, according to Lonza.